Treatment of ulcerative colitis

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Ulcerative colitis (UC) is a chronic inflammatory colon disease with unpredictable active and inactive phases.
• Effective management of UC focuses on inducing and maintaining remission through personalized treatment strategies.

Purpose of the Study:

• To review the management of ulcerative colitis (UC).
• To emphasize the role and efficacy of anti-tumor necrosis factor (TNF) agents in UC treatment.

Main Methods:

• Review of recent research and clinical studies on anti-TNF agents in UC.
• Comparative analysis of different anti-TNF therapies and conventional treatments.

Main Results:

• New anti-TNF agents, adalimumab (ADA) and golimumab, effectively induce and maintain remission in extensive UC.
• Infliximab demonstrates comparable efficacy to cyclosporine for acute, severe, corticosteroid-refractory UC.

Conclusions:

• Anti-TNF therapy is recommended for acute severe corticosteroid-refractory UC and moderate-to-severe UC unresponsive to conventional treatments.
• Adalimumab (ADA) and golimumab are viable alternatives to infliximab.
• Further research is necessary to evaluate the long-term efficacy and safety of ADA and golimumab in UC management.